Date post: | 25-Dec-2015 |
Category: |
Documents |
Upload: | domenic-hector-poole |
View: | 217 times |
Download: | 0 times |
De Luca A1,2, Bracciale L1, Doino M1, Fabbiani M1, Sidella L1, Marzocchetti A1, Farina S1, D’Avino A1,
Cauda R1, Di Giambenedetto S1
Safety and efficacy of treatment simplification to Atazanavir/ritonavir plus Lamivudine in patients on two NRTIs plus Atazanavir/ritonavir with optimal
virologic control: 24 weeks results from a pilot study (Atazanavir and Lamivudine Simplification Study,
ATLAS)
1Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
2Infectious Diseases Unit, Siena University Hospital, Siena, Italy
Introduction
• Long term toxicity and costs of cART highlight the need of treatment simplification strategies
• Monotherapy with boosted PIs has been investigated with controversial results
• Dual therapy could be a suitable option in certain patients
Atazanavir/ritonavir + lamivudine
• Tolerability: – ATV is a PI with a low metabolic impact; – 3TC generally very well tolerated.
• Once daily administration
• Relatively limited pill burden
• Relatively limited costs
ATLAS• Pilot study (40 patients)
– Prospective single-arm, single center, 48 weeks– Safety and tolerability– Max allowed failure rate (confirmed VL>50 cp/mL):
12.5%– Enrolment June 2009 – May 2010– Clinicaltrials.gov NCT00885482
• Inclusion criteria:– Patients on ATV/rit + 2 NRTIs from at least 3 months– HIV-RNA <50 copies/mL from at least 3 months– CD4 >200 cells/µL from at least 6 months
ATLAS• Exclusion criteria:
– Previous virological failure of 3TC or PI-containing regimens or exposure to mono-dual NRTI
– Virological failure with other regimens but a GRT with any RAM to 3TC or ATV
– Proton pump inhibitors co-administration
– HBsAg positive
– Pregnancy
ATLAS: study procedures• At baseline simplification to ATV/rit 300/100 mg OD +
3TC 300 mg OD
• Follow up visits at 4, 12, 24, 36 and 48 weeks
• At each visit: chemistry, CD4 and HIV-RNA, TDM, self reported adherence (VAS)
• At baseline and at 48 weeks: Quality of Life, self-reported symptoms, Neurocognitive assessment, Bone density (DXA), Fat distribution (DXA, Liposound), carotid IMT and endothelial function (brachial FMD)
Population: baseline characteristics (n=40) n (%)Age (years)* 45 (41-52)Male sex 23 (57.5)Foreign born 2 (5)Injecting drug users 9 (22.5)HCV co-infection 8 (20)Past AIDS-defining events 9 (22.5)Time from HIV diagnosis (years)* 11.4 (7.1-15.2)Time (years) from starting cART* 8.5 (6.3-10.2)Time (years) from starting last cART regimen* 2.6 (1.7-4.2)Tenofovir-containing NRTI backbone 39 (97.5)CD4 cells count (cells/µL)* 598 (483-778)CD4 cells count nadir (cells/µL)* 108 (45-223)Time (months) with viral load <50 copies/mL* 21 (10-30)
Values are expressed as n (%) except for *median (IQR)
• 40/40 patients completed Week 4, 38/40 Week 12, 36/40 week 24• All patients maintained an HIV-RNA<50copies/mL, without
viremic blips• No significant modifications of CD4 cells count
Results of 24 weeks interim analysis
P=0.277P=0.402
P=0.458
BL Week 4 Week 12
Week 24
0
20
40
60
80
100
120
100% 100% 100% 100%
Proportion of patients with HIV-RNA<50copies/mL Changes in CD4 cells count
Severe clinical adverse events
A total of 5 severe adverse events were observed in 5 patients :
• 2 renal colic• 1 hypertensive crisis• 1 brain hemorrhage
• 1 pregnancy (the only dropped patient)
Laboratory toxicity
• 14 patients with baseline grade 3 elevation of total bilirubin
• New grade 3 laboratory toxicities were observed in 18 pts
Grade 3
toxicities at baseline
New Grade 3 toxicities
Week 4 Week 12 Week 24 Total patients
Total bilirubin 14/40 (35%) 6/25 (24%) 9/24 (37.5%) 6/21 (28.6%) 13Total Cholesterol 2/38 (5.3%) 3/38 (7.9%) 1/36 (2.8%) 3LDL 2/35 (5.7%) 4/33 (12.2%) 2/35 (5.7%) 4Triglycerides 1/38 (2.6%) 1/38 (2.6%) 1Amylases 1/33 (3%) 1
Cholesterol changes from baselineM
ean
ch
ange
(m
g/d
L)
Baseline Week 4 Week 12 Week 24 pTC/HDL 4.3 (3.5-5.4) 4.2 (3.5-5.5) 4.4 (3.5-5.6) 4.4 (3.5-5.6) nsHDL/LDL 0.4 (0.3-0.5) 0.4 (0.3-0.5) 0.4 (0.3-0.5) 0.4 (0.3-0.5) ns
+20+18
+21
+4 +3 +4
+13
+9
+17P<0.01 for all parameters at all time points
Triglycerides changes from baseline
P=0.342
P=0.126
P=0.442
Renal function change from baselineM
ean
ch
ange
(m
g/d
l)
Mea
n c
han
ge (
mL
/min
/1.7
3m2 )
-0.04P=0.020
-0.06P=0.012
-0.08P<0.001
+6P=0.097
+4P=0.017
+6P<0.001
Bilirubin change from baselineM
ean
ch
ange
(m
g/d
L)
+0.3P=0.07
+0.1P=0.7
+0P=0.8
+0.3P=0.04
+0.1P=0.5
+0.1P=0.6
Changes in ATV plasma levels (C24h or C12h)
BL W4 W12 W24Patients 36 32 28 25
ATV geometric mean (GM) concentration (95% CI), mg/L
2.21 (0.22-5.76) 2.46 (0.63-5.70) 2.82 (0.48-7.58) 2.20 (0.04-10.2)
GM relative changes - +11.3% +27.6% -0.5%
P=0.925
P=0.469
P=0.664
Conclusions• Simplification regimen with ATV/rit+3TC maintained
virological suppression through 24 weeks
• 2 severe adverse events possibly related to drugs (renal colic); no severe laboratory adverse event; bilirubin increased temporarily.
• TC, HDL and LDL increased (a lipid-lowering effect of TDF was recently suggested)*; TC/HDL and HDL/LDL ratios were unchanged.
• Renal function improved significantly (probably due to TDF discontinuation)
*Tungsiripat M. AIDS. 2010 Jul 17;24:1781-4
Conclusions
• 48 weeks efficacy and safety results are necessary to confirm preliminary safety and efficacy of simplification to ATV/r+3TC
• Results will form the basis for definitive testing of this strategy in a randomized controlled trial.